TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26153378
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin three times a day for 7 days postoperatively
Study: 26153378
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin plus topical ciprofloxacin drops (4 drops three times a day for 3 days)
Study: 1611835
Drug: Ponalrestat (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponalrestat (600 mg day‐1)
Study: 6365809
Drug: sfericase (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sfericase (2 tablets, 3 times/day, total daily dose of 6 tablets)
Study: 29332024
Drug: Apotel (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apotel (1 g in 200 cc normal saline for 20 min)
Study: 29332024
Drug: Remifentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.5 μg/kg/min)
Study: 23480201
Drug: Basic oral
Normalized name: sodium phosphate, dibasic Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic oral hygiene instruction (Control)
Study: 20640546
Drug: Power Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Power Training (PT) and Hormone Replacement Therapy (HRT)
Study: 16286743
Drug: Lichtena plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lichtena plus 25 microg/g triamcinolone acetonide (TACA)
Study: 11898768
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C and E (200mg vitamin C and 50mg vitamin E, both twice per day for 4 weeks)
Study: 11898768
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (Bismuth chelate, tetracycline, and metronidazole for 2 weeks)
Study: 11898768
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Vitamins C and E + Triple therapy)
Study: 7599850
Drug: Methacholine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine (0.03 to 256 mg/ml)
Study: 1450684
Drug: Yeast-derived recombinant
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived recombinant vaccine 1
Study: 1450684
Drug: Yeast-derived recombinant
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived recombinant vaccine 2
Study: 6364880
Drug: control (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (5% ethanol solution)
Study: 29396000
Drug: Cycling of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycling of antibiotics (third-generation or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems)
Study: 29396000
Drug: Mixing strategy
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixing strategy (changing antibiotic to an alternative class for each consecutive patient)
Study: 27273879
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) - 30 kcal/kg/day, 0.16 gN/kg/day for 12 hours prior to operation
Study: 27273879
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion for 12 hours prior to operation
Study: 20703197
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release (ER) tablets, 3-15 mg/day (9 mg starting dose)
Study: 20703197
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release (ER) tablets
Study: 17113683
Drug: Tramadol/acetaminophen 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/acetaminophen 75 mg/650 mg
Study: 17113683
Drug: Hydrocodone/acetaminophen 7.5
Normalized name: hydrocodone/acetaminophen 7.5 mg-750 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen 7.5 mg/650 mg
Study: 16292444
Drug: Pro Root
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pro Root MTA (Dentsply) with 2% methylene blue solution
Study: 16292444
Drug: Zinc oxide-eugenol
Normalized name: Eugenol
DrugBank: Eugenol (DB09086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide-eugenol cement (ZOE) with 2% methylene blue solution
Study: 12111134
Drug: (131)I‐Lipiodol combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I‐Lipiodol combined with low-dose cisplatin (30 mg/m2)
Study: 12111134
Drug: (131)I‐Lipiodol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I‐Lipiodol therapy alone
Study: 12111134
Drug: (131)I‐Lipiodol combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I‐Lipiodol combined with low-dose cisplatin
Study: 1977779
Drug: Not taking
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not taking beta-blocker
Study: 20690865
Drug: Tibolone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (daily tablet for 6 months)
Study: 20690865
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hormone therapy)
Study: 16420289
Drug: NG ‐monomethyl‐L‐arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG ‐monomethyl‐L‐arginine (L‐NMMA)
Study: 8280821
Drug: sucralfate gel
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sucralfate gel (Gastrogel)
Study: 8280821
Drug: sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sucralfate suspension
Study: 3449067
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of piretanide (6 mg)
Study: 3449067
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of piretanide (6 mg)
Study: 29635492
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (FA) supplementation (400 µg/d)
Study: 27490103
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (2 capsules of 20 mg per day) and placebo of vitamin D (P+S)
Study: 25406653
Drug: Low-dose XJXGF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose XJXGF (10% of the XJXGF formula)
Study: 10232562
Drug: Epoprostenol (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol (prostaglandin I2), 500 microg intravenous bolus before cold perfusion
Study: 8553333
Drug: Doxazosin, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin, 4 mg daily
Study: 1704153
Drug: Tetracycline 1
Normalized name: tetracycline 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 1 g
Study: 6405939
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir cream applied topically five times a day for five days
Study: 24372302
Drug: Open-irrigated radiofrequency
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-irrigated radiofrequency catheter ablation (oiRFA) with saline volume administration
Study: 24372302
Drug: Furosemide administration
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide administration during LA ablation
Study: 18451770
Drug: Entrée with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrée with reduced energy density (1.2 kcal/g)
Study: 18451770
Drug: Entrée with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrée with decreased portion size (300 g)
Study: 18451770
Drug: Entrée with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrée with standard energy density (1.6 kcal/g)
Study: 31031186
Drug: 80 kV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 kV tube voltage, 350 mgI/kg contrast dose, ASIR‐V from 40% to 100%
Study: 31031186
Drug: 120 kV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 kV tube voltage, 600 mgI/kg contrast dose, 40% ASIR
Study: 27744624
Drug: SYM-1219 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYM-1219 (2 g secnidazole) with EE2 (0.035 mg) and NET (1 mg) tablets
Study: 27744624
Drug: SYM-1219 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYM-1219 (2 g secnidazole) followed by EE2 (0.035 mg) and NET (1 mg) tablets 1 day later
Study: 25395378
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day orally
Study: 20346518
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg daily for 12 weeks
Study: 17566844
Drug: docetaxel 70
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 70 mg/m(2) and carboplatin AUC 5
Study: 17566844
Drug: paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 175 mg/m(2) and carboplatin AUC 5
Study: 18400730
Drug: Sunflower-oil capsules
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower-oil capsules (3 g/d; control)
Study: 18400730
Drug: Cod (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod (3 x 150 g/wk)
Study: 18400730
Drug: Salmon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon (3 x 150 g/wk)
Study: 18400730
Drug: Fish-oil capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil capsules (3 g/d)
Study: 17038942
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) at doses of 40, 80, or 160 mug/kg
Study: 12655421
Drug: Daily inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily inhalation plus daily hydrotherapy
Study: 12655421
Drug: Daily inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily inhalation of normal saline (control)
Study: 11250737
Drug: Mathematical models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mathematical models for evaluating operative therapy
Study: 11250737
Drug: Mathematical models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mathematical models for chemotherapy administration
Study: 1439943
Drug: 2% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% clindamycin vaginal cream (5 g applied intravaginally at bedtime for 7 days) with placebo oral tablets twice daily for 7 days
Study: 1439943
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole tablets (500 mg twice a day for 7 days) with placebo vaginal cream (5 g intravaginally for 7 days)
Study: 16005362
Drug: Goshajinkigan (GJG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goshajinkigan (GJG) 7.5 g/day for 1 month
Study: 16005362
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GJG treatment)
Study: 9358963
Drug: nisoldipine CC
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nisoldipine CC
Study: 9358963
Drug: combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy (nisoldipine CC and lisinopril)
Study: 1389940
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg zidovudine after a 25 g protein meal
Study: 1389940
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg zidovudine in a fasting state
Study: 3930309
Drug: Deteclo (tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deteclo (tetracycline hydrochloride, chlortetracycline hydrochloride, and demeclocycline hydrochloride 300 mg)
Study: 27348923
Drug: Conical stone
Normalized name: ditch stonecroft extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical stone needle on foot combined with bian anvil at Yintang (CV 29), applied at Yongquan (KI 1), Taichong (LR 3), and Gongsun (SP 4) for 2 weeks, once a day with 2 days rest between treatments.
Study: 27348923
Drug: Common acupuncture
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common acupuncture at Sanyinjiao (SP 6), Shenmen (HT 7), and Sishencong (EX-HN 1) for 2 weeks, once a day with 2 days rest between treatments.
Study: 27348923
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups were followed up after treatment.
Study: 24682079
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral thoracic paravertebral block with 0.25% ropivacaine 0.5 mL/kg and 1:200,000 epinephrine
Study: 24682079
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous PCA)
Study: 23006443
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Bisocard® 10 mg)
Study: 23006443
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Concor 10®)
Study: 17629805
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) with dosage 1.5 J/per point, applied once a day for 10 days.
Study: 17629805
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy (control group).
Study: 9432092
Drug: Maximal graded
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal graded treadmill test (VO2max = 30.3 +/- 5.7 mL x min‐1 x kg‐1)
Study: 3103412
Drug: Intermittent transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent transdermal nitroglycerin (16 hours/day)
Study: 3103412
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal nitroglycerin (24 hours/day)
Study: 3103412
Drug: Control value
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control value (before treatment)
Study: 25867538
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg dose intravenously)
Study: 12815913
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE), 0.625 mg/d, and medroxyprogesterone acetate (MPA), 5 mg/d
Study: 12815913
Drug: Tibolone, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone, 2.5 mg/d
Study: 8774205
Drug: Oral estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol, 2 mg/d for the first 6 months
Study: 1465288
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) with metoclopramide (MCP) 1.5 mg/kg (group B)
Study: 1465288
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) with metoclopramide (MCP) 2 mg/kg (group D)
Study: 1465288
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 1.5 mg/kg (group A)
Study: 1465288
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 2 mg/kg (group C)
Study: 25748642
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of brinzolamide 1% and timolol 0.5% (FCBT)
Study: 25022107
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection combined with plum-blossom needle
Study: 25022107
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (control group)
Study: 15936419
Drug: Three rounds
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three rounds of oral visual inspection by trained health workers at 3-year intervals (intervention group)
Study: 12183788
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg depot dexamethasone combined with 60 mg lidocaine
Study: 8758853
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 'Nao An' capsules
Study: 6357037
Drug: Avoiding antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoiding antibiotic prophylaxis
Study: 29543123
Drug: Self‐administered Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered Foam Rolling (SAFR)
Study: 28089316
Drug: Beta-blockers (time-dependent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (time-dependent variable)
Study: 26102300
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HPMC and povidone
Study: 24408214
Drug: High-dose (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (35 mg) nicotine patch
Study: 19200452
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose regimen (1 x 12 microg)
Study: 19200452
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (2 doses of 6 microg with a 28-day interval)
Study: 17971615
Drug: Computerized Dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized Dynamic Posturography (CDP) therapy
Study: 17971615
Drug: Standard Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Physical Therapy (PT)
Study: 11209831
Drug: Measured total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measured total daily exposure time
Study: 9743393
Drug: Epidural morphine-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine-bupivacaine (0.05 mg/kg epidural morphine and 5 ml 0.25% bupivacaine followed by an infusion of 0.125% bupivacaine with 0.1% morphine)
Study: 9743393
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA morphine sulfate (0.1 mg/kg)
Study: 9743393
Drug: Epidural morphine-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine-bupivacaine
Study: 9743393
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA morphine sulfate
Study: 28578639
Drug: ADT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily)
Study: 17201848
Drug: High BNP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High BNP concentration (>18.4 pg/mL)
Study: 8759075
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 to 90 mg TID)
Study: 6750282
Drug: Tolmetin (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmetin (1,200 mg/day)
Study: 6750282
Drug: Paracetamol (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (2,000 mg/day)
Study: 24114668
Drug: Continuous erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous erlotinib (100 mg daily)
Study: 24114668
Drug: Intermittent erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent erlotinib (150 mg on alternate days from day 2 to 14, then 150 mg daily on days 15 to 21)
Study: 22120894
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg ginkgo extract tablets, three times daily for 30 days
Study: 18369175
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel combined
Study: 9167505
Drug: Sertindole 12
Normalized name: sertindole 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 12 mg/day
Study: 9167505
Drug: Haloperidol 4
Normalized name: haloperidol 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 4 mg/day
Study: 9167505
Drug: Haloperidol 8
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 8 mg/day
Study: 7681897
Drug: Prazosin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (6 mg/day)
Study: 23807186
Drug: Cataract surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cataract surgery plus intraoperative ranibizumab injection
Study: 17081355
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride concluding heparin (control)
Study: 14692654
Drug: TOR200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOR200 (200 mg daily)
Study: 14692654
Drug: TAM20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM20 (20 mg daily)
Study: 11013867
Drug: Smoking group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking group (mean cotinine concentration 1039 +/- 560 mg/L in serum)
Study: 4028282
Drug: Tinidazole 2
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2 g daily taken orally in two separate doses for two consecutive days
Study: 15954914
Drug: EPO administration
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO administration (50 units per kg once per week) in group II
Study: 15954914
Drug: No EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No EPO treatment in group III
Study: 8046602
Drug: Regular release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular release formulation of tiaprofenic acid (300 mg)
Study: 8046602
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release (SR) formulation of tiaprofenic acid (300 mg)
Study: 15114082
Drug: Celsior solution
Normalized name: Fraxinus excelsior leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celsior solution